67 related articles for article (PubMed ID: 22170343)
1. Coxsackievirus B3 used as a gene therapy vector to express functional FGF2.
Kim DS; Kim H; Shim SH; Kim C; Song M; Kim YH; Jung YW; Nam JH
Gene Ther; 2012 Dec; 19(12):1159-65. PubMed ID: 22170343
[TBL] [Abstract][Full Text] [Related]
2. Long-term cardiac gene expression using a coxsackieviral vector.
Lim BK; Shin JO; Lee SC; Kim DK; Choi DJ; Choe SC; Knowlton KU; Jeon ES
J Mol Cell Cardiol; 2005 May; 38(5):745-51. PubMed ID: 15850568
[TBL] [Abstract][Full Text] [Related]
3. Systemic analysis of a novel coxsackievirus gene delivery system in a mouse model.
Kim YJ; Yun SH; Lim BK; Park KB; Na HN; Jeong SY; Kim DS; Cho YJ; Jeon ES; Nam JH
J Microbiol Biotechnol; 2009 Mar; 19(3):307-13. PubMed ID: 19349757
[TBL] [Abstract][Full Text] [Related]
4. Foreign gene transfer to cardiomyocyte using a replication-defective recombinant coxsackievirus B3 without cytotoxicity.
Lim BK; Yun SH; Gil CO; Ju ES; Choi JO; Kim DK; Jeon ES
Intervirology; 2012; 55(3):201-9. PubMed ID: 21821992
[TBL] [Abstract][Full Text] [Related]
5. Systematic analysis of attenuated Coxsackievirus expressing a foreign gene as a viral vaccine vector.
Kim DS; Cho YJ; Kim BG; Lee SH; Nam JH
Vaccine; 2010 Feb; 28(5):1234-40. PubMed ID: 19941986
[TBL] [Abstract][Full Text] [Related]
6. An attenuated coxsackievirus b3 vector: a potential tool for viral tracking study and gene delivery.
Zeng J; Chen Xx; Dai Jp; Zhao Xf; Xin G; Su Y; Wang Gf; Li R; Yan Yx; Su Jh; Deng Yx; Li Ks
PLoS One; 2013; 8(12):e83753. PubMed ID: 24386270
[TBL] [Abstract][Full Text] [Related]
7. Appropriate control of ex vivo gene therapy delivering basic fibroblast growth factor promotes successful and safe development of collateral vessels in rabbit model of hind limb ischemia.
Ishii S; Koyama H; Miyata T; Nishikage S; Hamada H; Miyatake S; Shigematsu H
J Vasc Surg; 2004 Mar; 39(3):629-38. PubMed ID: 14981459
[TBL] [Abstract][Full Text] [Related]
8. Application of attenuated coxsackievirus B3 as a viral vector system for vaccines and gene therapy.
Kim DS; Nam JH
Hum Vaccin; 2011 Apr; 7(4):410-6. PubMed ID: 21389776
[TBL] [Abstract][Full Text] [Related]
9. Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis.
Shen Y; Xu W; Chu YW; Wang Y; Liu QS; Xiong SD
J Virol; 2004 Nov; 78(22):12548-56. PubMed ID: 15507642
[TBL] [Abstract][Full Text] [Related]
10. Destabilization of coxsackievirus b3 genome integrated with enhanced green fluorescent protein gene.
Tong L; Lin L; Zhao W; Wang B; Wu S; Liu H; Zhong X; Cui Y; Gu H; Zhang F; Zhong Z
Intervirology; 2011; 54(5):268-75. PubMed ID: 21242657
[TBL] [Abstract][Full Text] [Related]
11. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration.
Song X; Liu Z; Wang H; Xin Y; Wang X; Chen J; Shi Y; Zhang C; Hui R
Exp Biol Med (Maywood); 2007 Dec; 232(11):1441-8. PubMed ID: 18040068
[TBL] [Abstract][Full Text] [Related]
12. Delivery of fibroblast growth factor 2 enhances the viability of cord blood-derived mesenchymal stem cells transplanted to ischemic limbs.
Bhang SH; Lee TJ; La WG; Kim DI; Kim BS
J Biosci Bioeng; 2011 May; 111(5):584-9. PubMed ID: 21388874
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
Zhang L; Parham NJ; Zhang F; Aasa-Chapman M; Gould EA; Zhang H
Vaccine; 2012 Mar; 30(13):2301-8. PubMed ID: 22306858
[TBL] [Abstract][Full Text] [Related]
14. HSV-1 vector-delivered FGF2 to the retina is neuroprotective but does not preserve functional responses.
Spencer B; Agarwala S; Gentry L; Brandt CR
Mol Ther; 2001 May; 3(5 Pt 1):746-56. PubMed ID: 11356079
[TBL] [Abstract][Full Text] [Related]
15. Role of GNRA motif mutations within stem-loop V of internal ribosome entry segment in coxsackievirus B3 molecular attenuation.
M'hadheb-Gharbi MB; El Hiar R; Paulous S; Jaïdane H; Aouni M; Kean KM; Gharbi J
J Mol Microbiol Biotechnol; 2008; 14(4):147-56. PubMed ID: 17693702
[TBL] [Abstract][Full Text] [Related]
16. 1A and 3D gene sequences of coxsackievirus B3 strain CC: variation and phylogenetic analysis.
Liu MY; Wu DL; Liu NH; Meng QW; Meng FC
DNA Seq; 2008 Feb; 19(1):8-12. PubMed ID: 17852360
[TBL] [Abstract][Full Text] [Related]
17. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
[TBL] [Abstract][Full Text] [Related]
18. Mutation variants generated from nonvirulent coxsackievirus B3 acquire virulence phenotypes by active virus replication.
Seo I; Jee Y; Ahn J; Jun EJ; Kim D; Joo CH; Kim YK; Lee H
Intervirology; 2007; 50(6):447-53. PubMed ID: 18268408
[TBL] [Abstract][Full Text] [Related]
19. Combined delivery of heme oxygenase-1 gene and fibroblast growth factor-2 protein for therapeutic angiogenesis.
Bhang SH; Kim JH; Yang HS; La WG; Lee TJ; Sun AY; Kim GH; Lee M; Kim BS
Biomaterials; 2009 Oct; 30(31):6247-56. PubMed ID: 19682740
[TBL] [Abstract][Full Text] [Related]
20. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
